Pipeline of small molecule therapeutics
InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications.
Targeting CB1 and CB2 pathways
InMed has initiated three pharmaceutical programs – including preclinical programs in Alzheimer’s disease and age-related macular degeneration, as well as a completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.
InMed’s small molecule compounds are demonstrating promising effects with potentially multiple mechanisms.
INM-901 demonstrates a multi-factorial approach to treating Alzheimer’s disease
INM-901 demonstrates multiple pharmacological effects in preclinical studies including neuroprotective effects, an ability to extend the length of neurites which is important for brain cell-to-cell communication, as well as a reduction in neuroinflammation. These preclinical studies were conducted in well-characterized study models of Alzheimer’s disease.
INM-089 for Dry AMD Demonstrates Functional and Pathological Improvements in Preclinical Study
INM-089 has demonstrated its ability to proactively protect the nerve cells in the back of the eye in the retinal area, exhibiting its therapeutic potential in dry age-related macular degeneration (AMD).
Preclinical studies of INM-089 demonstrated significant functional and pathological improvements in a dry AMD disease study model. Results from studies demonstrate that INM-089 provides neuroprotection of photoreceptors, improves photoreceptor function and the integrity of the retinal pigment epithelium and reduces extracellular auto fluorescent deposits, a hallmark of dry AMD.
Bringing you highly pure, premium bioidentical rare cannabinoids
InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. We have engineered bioidentical cannabinoids with high purity and consistency, and free of THC. We currently manufacture the rare, minor cannabinoids cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and cannabicitran (CBTC) which are available for B2B purchase.
Experienced team with a successful track record
Together, InMed and BayMedica bring extensive know-how in pharmaceutical research and development and manufacturing. We’ve combined our complementary expertise to become a leading pharmaceutical R&D company and manufacturer of small molecule therapeutics targeting CB1/CB2 receptors.
